Filing Details
- Accession Number:
- 0001192482-20-000291
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2020-04-20 19:42:31
- Reporting Period:
- 2020-04-17
- Accepted Time:
- 2020-04-20 19:42:31
- Original Submission Date:
- 2020-04-20
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1588972 | Recro Pharma Inc. | REPH | () | 4/A |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1236451 | Geraldine Henwood | C/O Recro Pharma, Inc. 490 Lapp Road Malvern PA 19355 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-04-17 | 80,000 | $2.47 | 321,194 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2020-04-17 | 80,000 | $8.22 | 241,194 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2020-04-17 | 80,000 | $0.00 | 80,000 | $2.47 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2024-12-16 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 50,000 | Indirect | By: Spouse |
Footnotes
- This amended Form 4 is being filed to reflect an exercise of options that occurred on the same day as the transaction.
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.51, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4.
- The shares subject to this option are fully vested and exercisable.
Billionaire Hedge Funds
